Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 263

1.

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation.

Döring M, Blume O, Haufe S, Hartmann U, Kimmig A, Schwarze CP, Lang P, Handgretinger R, Müller I.

Eur J Clin Microbiol Infect Dis. 2014 Apr;33(4):629-38. doi: 10.1007/s10096-013-1998-2. Epub 2013 Oct 31.

2.

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.

Döring M, Müller C, Johann PD, Erbacher A, Kimmig A, Schwarze CP, Lang P, Handgretinger R, Müller I.

BMC Infect Dis. 2012 Oct 19;12:263. doi: 10.1186/1471-2334-12-263.

3.

Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.

Döring M, Eikemeier M, Cabanillas Stanchi KM, Hartmann U, Ebinger M, Schwarze CP, Schulz A, Handgretinger R, Müller I.

Eur J Clin Microbiol Infect Dis. 2015 Jun;34(6):1189-200. doi: 10.1007/s10096-015-2340-y. Epub 2015 Feb 14.

4.

Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.

Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, Miller PJ, Ribaud P, Schlamm HT, Solano C, Cook G; IMPROVIT Study Group.

Br J Haematol. 2011 Nov;155(3):318-27. doi: 10.1111/j.1365-2141.2011.08838.x. Epub 2011 Aug 22.

5.

Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.

Ziakas PD, Kourbeti IS, Mylonakis E.

Clin Ther. 2014 Feb 1;36(2):292-306.e1. doi: 10.1016/j.clinthera.2013.11.010. Epub 2014 Jan 17.

PMID:
24439393
6.

Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.

Lin R, Xu X, Li Y, Sun J, Fan Z, Jiang Q, Huang F, Zhou H, Nie D, Guo Z, Mao Y, Xiao Y, Liu Q.

Transpl Infect Dis. 2014 Apr;16(2):286-94. doi: 10.1111/tid.12192. Epub 2014 Mar 5.

PMID:
24593273
7.

Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.

Wang CH, Kan LP, Lin HA, Chang FY, Wang NC, Lin TY, Chao TY, Kao WY, Ho CL, Chen YC, Dai MS, Chang PY, Wu YY, Lin JC.

J Microbiol Immunol Infect. 2016 Aug;49(4):531-8. doi: 10.1016/j.jmii.2014.07.009. Epub 2014 Oct 13.

8.

Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation.

Sánchez-Ortega I, Patiño B, Muñoz C, Arnan M, Peralta T, Clopés A, de Sevilla AF, Duarte RF.

J Med Econ. 2013;16(6):736-43. doi: 10.3111/13696998.2013.791301. Epub 2013 Apr 12.

PMID:
23541251
9.

Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.

Chaftari AM, Hachem RY, Ramos E, Kassis C, Campo M, Jiang Y, Prince RA, Wang W, Raad II.

Transplantation. 2012 Aug 15;94(3):302-8. doi: 10.1097/TP.0b013e3182577485.

PMID:
22814329
10.

Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.

Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC.

Ann Intern Med. 2003 May 6;138(9):705-13.

PMID:
12729424
11.

Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.

Solano C, Slavin M, Shaul AJ, Marks DI, Cordonnier C, Cornely OA, Pagliuca A, Cragin L, Jarque I, Garcia-Vidal C, Sorensen S, Vanness DJ, Charbonneau C, Barrueta JA, Peral C, De Salas-Cansado M, Bow EJ.

Mycoses. 2017 Feb;60(2):79-88. doi: 10.1111/myc.12552. Epub 2016 Aug 26.

PMID:
27562016
12.

Newer antifungal agents for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis.

Xu SX, Shen JL, Tang XF, Feng B.

Transplant Proc. 2013 Jan-Feb;45(1):407-14. doi: 10.1016/j.transproceed.2012.07.149.

PMID:
23375330
14.

Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.

Ananda-Rajah MR, Grigg A, Downey MT, Bajel A, Spelman T, Cheng A, Thursky KT, Vincent J, Slavin MA.

Haematologica. 2012 Mar;97(3):459-63. doi: 10.3324/haematol.2011.051995. Epub 2011 Nov 4.

15.

Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.

Döring M, Cabanillas Stanchi KM, Queudeville M, Feucht J, Blaeschke F, Schlegel P, Feuchtinger T, Lang P, Müller I, Handgretinger R, Heinz WJ.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1281-1292. doi: 10.1007/s00432-017-2369-7. Epub 2017 Mar 3.

PMID:
28258343
16.

Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.

Cho SY, Lee DG, Choi JK, Lee HJ, Kim SH, Park SH, Choi SM, Choi JH, Yoo JH, Kim YJ, Kim HJ, Min WS, Back H, Kang S, Lee EK.

Clin Ther. 2015 Sep;37(9):2019-27. doi: 10.1016/j.clinthera.2015.06.014. Epub 2015 Jul 15.

17.

Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation.

Sánchez-Ortega I, Patiño B, Arnan M, Peralta T, Parody R, Gudiol C, Encuentra M, Fernández de Sevilla A, Duarte RF.

Bone Marrow Transplant. 2011 May;46(5):733-9. doi: 10.1038/bmt.2010.185. Epub 2010 Aug 9.

PMID:
20697369
18.

Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.

Vehreschild MJ, von Bergwelt-Baildon M, Tran L, Shimabukuro-Vornhagen A, Wisplinghoff H, Bangard C, Cornely OA, Vehreschild JJ.

Eur J Haematol. 2014 Nov;93(5):400-6. doi: 10.1111/ejh.12368. Epub 2014 May 26.

PMID:
24798021
19.

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D.

N Engl J Med. 2007 Jan 25;356(4):348-59.

20.

Reduction in incidence of invasive fungal infection in patients receiving allogeneic stem cell transplantation using combined diagnostic-driven approach and itraconazole oral solution.

Tzadok R, Shapira MY, Moses AE, Or R, Block C, Strahilevitz J.

Mycoses. 2015 Dec;58(12):694-8. doi: 10.1111/myc.12416. Epub 2015 Oct 2.

PMID:
26429354

Supplemental Content

Support Center